Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, January 2002, p. 234-238, Vol. 46, No. 1
0066-4804/01/$04.00+0 DOI: 10.1128/AAC.46.1.234-238.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.
Antimicrobial Activities of BMS-284756 Compared with Those of Fluoroquinolones and ß-Lactams against Gram-Positive Clinical Isolates
Matteo Bassetti,1* Louise M. Dembry,1,2 Patricia A. Farrel,2 Deborah A. Callan,2 and Vincent T. Andriole1
Yale University School of Medicine,1
Yale-New Haven Hospital New Haven, Connecticut2
Received 27 April 2001/
Returned for modification 30 July 2001/
Accepted 5 October 2001
The in vitro antibacterial activity of BMS-284756 was compared to those of ciprofloxacin, gatifloxacin, moxifloxacin, ceftriaxone, imipenem, piperacillin-tazobactam, and amoxicillin-clavulanic acid against 492 gram-positive clinical isolates. BMS-284756 was the most-active agent against Streptococcus pneumoniae, Streptococcus viridans, beta-hemolytic streptococci, methicillin-sensitive and -resistant Staphylococcus aureus, methicillin-sensitive and -resistant coagulase-negative staphylococci, and enterococci.
* Corresponding author. Mailing address: Clinica Malattie Infettive, Universitá di Genova, Ospedale San Martino, Largo R. Benzi, 10, 16132 Genova, Italy. Phone: 39 010 5552668. Fax: 39 010 3537680. E-mail:
mattba{at}tin.it.
Antimicrobial Agents and Chemotherapy, January 2002, p. 234-238, Vol. 46, No. 1
0066-4804/01/$04.00+0 DOI: 10.1128/AAC.46.1.234-238.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.
This article has been cited by other articles:
-
Krishna, G., Kisicki, J. C., Olsen, S., Grasela, D. M., Wang, Z.
(2007). The Effect of Omeprazole on the Bioavailability and Safety of Garenoxacin in Healthy Volunteers. J Clin Pharmacol
47: 628-632
[Abstract]
[Full Text]
-
Anguita-Alonso, P., Rouse, M. S., Piper, K. E., Steckelberg, J. M., Patel, R.
(2006). Garenoxacin treatment of experimental endocarditis caused by viridans group streptococci.. Antimicrob. Agents Chemother.
50: 1263-1267
[Abstract]
[Full Text]
-
Christiansen, K. J., Bell, J. M., Turnidge, J. D., Jones, R. N.
(2004). Antimicrobial Activities of Garenoxacin (BMS 284756) against Asia-Pacific Region Clinical Isolates from the SENTRY Program, 1999 to 2001. Antimicrob. Agents Chemother.
48: 2049-2055
[Abstract]
[Full Text]
-
Liebetrau, A., Rodloff, A. C., Behra-Miellet, J., Dubreuil, L.
(2003). In Vitro Activities of a New Des-Fluoro(6) Quinolone, Garenoxacin, against Clinical Anaerobic Bacteria. Antimicrob. Agents Chemother.
47: 3667-3671
[Abstract]
[Full Text]
-
Credito, K. L., Jacobs, M. R., Appelbaum, P. C.
(2003). Time-Kill Studies of the Antianaerobe Activity of Garenoxacin Compared with Those of Nine Other Agents. Antimicrob. Agents Chemother.
47: 1399-1402
[Abstract]
[Full Text]
-
Hecht, D. W., Osmolski, J. R.
(2003). Activities of Garenoxacin (BMS-284756) and Other Agents against Anaerobic Clinical Isolates. Antimicrob. Agents Chemother.
47: 910-916
[Abstract]
[Full Text]
-
Pankuch, G. A., Jacobs, M. R., Appelbaum, P. C.
(2003). Postantibiotic Effects of Garenoxacin (BMS-284756) against 12 Gram-Positive or -Negative Organisms. Antimicrob. Agents Chemother.
47: 1140-1142
[Abstract]
[Full Text]